Mettler Toledo International Inc/
MTD · NYSELaboratory Analytical Instruments · Fiscal year ends Dec 31
Mettler Toledo International Inc/ reported revenue of $4B in the fiscal year ended Dec 2025, up 4.0% from the year before. Net income was $869M. Operating cash flow of $956M less capital expenditure of $107M left free cash flow of $849M. Net debt was $2.1B.
Last 5 fiscal years
Revenue and net income
Income statement
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | $3.7B | $3.9B | $3.8B | $3.9B | $4B |
| Gross profit | $2.2B | $2.3B | $2.2B | $2.3B | $2.4B |
| Research & development | $170M | $177M | $185M | $189M | $199M |
| Selling, general & admin | $944M | $938M | $904M | $936M | $998M |
| Interest expense | $43M | $55M | $77M | $75M | $69M |
| Pre-tax income | $949M | $1.1B | $974M | $1B | $1B |
| Income tax | $180M | $198M | $185M | $174M | $180M |
| Net income | $769M | $873M | $789M | $863M | $869M |
| Diluted EPS | 32.78 | 38.41 | 35.90 | 40.48 | 42.05 |
| Diluted shares | 23M | 23M | 22M | 21M | 21M |
Balance sheet
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Cash & equivalents | $99M | $96M | $70M | $59M | $67M |
| Receivables | $647M | $709M | $664M | $687M | $778M |
| Inventory | $415M | $442M | $386M | $342M | $387M |
| Current assets | $1.3B | $1.4B | $1.2B | $1.2B | $1.4B |
| Net PP&E | $799M | $779M | $803M | $770M | $846M |
| Goodwill | $649M | $660M | $670M | $669M | $739M |
| Total assets | $3.3B | $3.5B | $3.4B | $3.2B | $3.7B |
| Payables | $273M | $253M | $210M | $216M | $267M |
| Deferred revenue | $193M | $193M | $202M | $204M | $229M |
| Current liabilities | $1.1B | $1.1B | $1.2B | $1.2B | $1.2B |
| Short-term debt | $101M | $106M | $192M | $183M | $64M |
| Long-term debt | $1.6B | $1.9B | $1.9B | $1.8B | $2.1B |
| Total liabilities | $3.2B | $3.5B | $3.5B | $3.4B | $3.7B |
| Shareholders' equity | $171M | $25M | −$150M | −$127M | −$24M |
Cash flow
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating cash flow | $909M | $859M | $966M | $968M | $956M |
| Capital expenditure | $108M | $121M | $105M | $104M | $107M |
| Free cash flow | $801M | $738M | $861M | $864M | $849M |
| Depreciation & amortisation | $45M | $47M | $49M | $50M | $51M |
| Stock-based compensation | $20M | $20M | $18M | $20M | $23M |
| Acquisitions | $221M | $38M | $6M | $10M | $94M |
| Share buybacks | $1,000M | $1.1B | $900M | $850M | $800M |
Key ratios
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue growth (YoY) | – | 5.4% | −3.4% | 2.2% | 4.0% |
| EPS growth (YoY) | – | 17.2% | −6.5% | 12.8% | 3.9% |
| Gross margin | 58.4% | 58.9% | 59.2% | 60.1% | 59.4% |
| Net margin | 20.7% | 22.3% | 20.8% | 22.3% | 21.6% |
| Return on equityBlank when equity is negative | 448.6% | 3519.1% | – | – | – |
| Free cash flow margin | 21.6% | 18.8% | 22.7% | 22.3% | 21.1% |
| Cash conversion (CFO ÷ net income) | 1.18x | 0.98x | 1.22x | 1.12x | 1.10x |
| Receivable days | 64 | 66 | 64 | 65 | 71 |
| Inventory days | 98 | 100 | 91 | 81 | 86 |
| Payable days | 64 | 57 | 50 | 51 | 59 |
| Debt ÷ equity | 9.81x | 81.3x | – | – | – |
| Net debtDebt − cash & equivalents; excludes investments; negative = net cash | $1.6B | $1.9B | $2B | $2B | $2.1B |
| Current ratio | 1.11x | 1.20x | 1.04x | 1.02x | 1.14x |
Recent filings
More in Laboratory Analytical Instruments
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.